Future Outlooks in an Evolving Landscape for R/R DLBCL

Opinion
Video

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

Related Videos
Related Content